Long-term Efficacy of Radiofrequency Ablation Combined with Chemotherapy in the Treatment of Patients with Advanced Non-small Cell Lung Cancer--A Retrospective Study
10.3779/j.issn.1009-3419.2017.10.03
- VernacularTitle:射频消融术联合化疗治疗进展期非小细胞肺癌远期疗效的回顾性研究
- Author:
DU SHUHUI
1
;
QIN DA
;
PANG RUIQI
;
ZHANG YEQING
;
ZHAO SIQI
;
HU MU
;
ZHI XIUYI
Author Information
1. 首都医科大学宣武医院胸外科
- Keywords:
Lung neoplasms;
Radiofrequency ablation;
Chemotherapy;
Long-term efficacy
- From:
Chinese Journal of Lung Cancer
2017;20(10):675-682
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Radiofrequency ablation (RFA) combined with chemotherapy has a certain short-term therapeutic effect for the treatment of advanced non-small cell lung cancer (NSCLC), but whether it can improve the long-term survival rate of patients is still controversy. This study retrospectively analyzed the difference of long-term effi-cacy between RFA combined with chemotherapy and chemotherapy alone in the treatment of patients with advanced NSCLC. Methods A total of 77 patients with stage IIIb and stage IV NSCLC who underwent radiofrequency ablation and chemo-therapy in the Department of Thoracic Surgery, Xuanwu Hospital, Capital University of Medical Sciences from September 2009 to December 2015 were enrolled as the treatment group. Chemotherapy with no radiofrequency ablation was performed in 56 patients with stage IIIb and stage IV NSCLC as the control group. Two groups of patients were followed up by telephone about their living conditions. "Survival" package of R software version 3.4.1 was used for statistical analysis. Two sets of data baseline levels were tested by chi-square test.The bias was processed by Cox regression model and the survival curve was plot-ted using covariate mean substitution method. Results The first-year survival rate of the treatment group was 70.74%, the two-year survival rate was 39.31% and the median survival time was 22.1 months. The one-year survival rate was 54.54% in the control group, the two-year survival rate was 19.49%, the median survival for 18.1 months. The long-term survival rate of the treatment group was better than that of the control group (P<0.05, OR=0.571). Conclusion Radiofrequency ablation of lung cancer combined with chemotherapy can significantly improve the 2-year survival rate of patients with stage IIIb and stage IV NSCLC.
